Significant Influence of Cardiac Radiation Dose on the Risk of Cardiotoxicity in Patients Receiving Adjuvant Trastuzumab and Radiation Therapy for Breast Cancer
Authors
Tae Hoon Lee, MD, PhD, Nalee Kim, MD, PhD, Eun Kyoung Kim, MD, PhD,y Jin Seok Ahn, MD, PhD, Yeon Hee Park, MD, PhD, Seok Won Kim, MD, PhD, Jeong Eon Lee, MD, PhD, Jonghan Yu, MD, PhD, Byung Joo Chae, MD, PhD, Se Kyung Lee, MD, PhD, Won Kyung Cho, MD, Won Park, MD, PhD, Tae Gyu Kim, MD, PhD, Jee Suk Chang, MD, PhD, and Haeyoung Kim, MD, PhD
Journal
International Journal of Radiation Oncology, Biology, Physics
This study analyzed the impact of adjuvant Trastuzumab and Radiation Therapy (RT) on the risk of cardiotoxicity in HER2-positive breast cancer patients. A retrospective study of 1378 patients revealed that a higher Cardiac Radiation Dose was associated with an increased risk of Cancer Therapy-Related Cardiovascular Toxicity (CTRCVT). CTRCVT occurred during Trastuzumab treatment (3.0%) or after completion of Trastuzumab (2.2%), with a higher incidence observed in patients receiving greater cardiac radiation exposure. Notably, patients with heart V25Gy ≥ 3.0% exhibited a CTRCVT rate of 5.7%. The study utilized Coreline Soft’s Aview RT ACS for automated cardiac structure segmentation and radiation dose analysis, elucidating the correlation between cardiac radiation dose and CTRCVT. These findings contribute to the development of radiation therapy strategies to minimize cardiotoxicity in patients undergoing combined Trastuzumab and RT treatment.
목록으로
